(Q49185595)

19 February 2018

editorial

0 references

title

IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications. (English)

1 reference

19 February 2018

0 references

Darrell R Borger

1

1 reference

19 February 2018

Andrew X Zhu

series ordinal

2

1 reference

19 February 2018

publication date

1 May 2012

1 reference

19 February 2018

Expert Review of Anticancer Therapy

published in

1 reference

19 February 2018

volume

12

1 reference

19 February 2018

issue

5

1 reference

19 February 2018

page(s)

543-546

1 reference

19 February 2018

Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?

cites work

1 reference

21 January 2018

Global cancer statistics

1 reference

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

21 January 2018

1 reference

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

21 January 2018

1 reference

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

21 January 2018

1 reference

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy

21 January 2018

1 reference

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 January 2018

1 reference

O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment

21 January 2018

1 reference

TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.12.32

1 reference

19 February 2018

1 reference

19 February 2018